{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:15:19Z","timestamp":1790806519851,"version":"4.1.0"},"reference-count":106,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timisoara, Romania"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Introduction: Diabetes mellitus (DM) has a millennia-long history, with early references dating back to ancient Egypt and India. However, it was not until the 20th century that the connection between diabetes and insulin was fully understood. The sequencing of insulin in the 1950s initiated the convergence of biotechnology and diabetes management, leading to the development of recombinant human insulin in 1982. This marked the start of peptide-based therapies in DM. Recombinant peptides for DM treatment: Numerous recombinant peptides have been developed since, starting with modified insulin molecules, with the aim of bettering DM management through fine-tuning the glycemic response to insulin. Peptide-based therapies in DM have expanded substantially beyond insulin to include agonists of Glucagon-like peptide-1 receptor and Glucose-dependent insulinotropic polypeptide receptor, glucagon receptor antagonists, and even peptides exerting multiple receptor agonist effects, for better metabolic control. Insulin pumps, continuous glucose monitoring, and automated insulin delivery systems: The development of modern delivery systems combined with real-time glucose monitoring has significantly advanced diabetes care. Insulin pumps evolved from early large devices to modern sensor-augmented pumps with automated shutoff features and hybrid closed-loop systems, requiring minimal user input. The second-generation systems have demonstrated superior outcomes, proving highly effective in diabetes management. Islet cell transplantation, organoids, and biological pancreas augmentation represent innovative approaches to diabetes management. Islet cell transplantation aims to restore insulin production by transplanting donor beta cells, though challenges persist regarding graft survival and the need for immunosuppression. Organoids are a promising platform for generating insulin-producing cells, although far from clinical use. Biological pancreas augmentation relies on therapies that promote beta-cell (re)generation, reduce stress, and induce immune tolerance. Further biotechnology-driven perspectives in DM will include metabolic control via biotechnology-enabled tools such as custom-designed insulin hybrid molecules, machine-learning algorithms to control peptide release, and engineering cells for optimal peptide production and secretion.<\/jats:p>","DOI":"10.3390\/biom14121563","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T04:01:37Z","timestamp":1733716897000},"page":"1563","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Biotechnology Revolution Shaping the Future of Diabetes Management"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2824-7182","authenticated-orcid":false,"given":"Nilima Rajpal","family":"Kundnani","sequence":"first","affiliation":[{"name":"Department of Cardiology\u2014Internal Medicine and Ambulatory Care, Prevention and Cardiovascular Recovery, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Research Centre of Timisoara Institute of Cardiovascular Diseases, \u201cVictor Babe\u0219s\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Lolescu","sequence":"additional","affiliation":[{"name":"Doctoral School Medicine-Pharmacy, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy from Timisoara, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2950-673X","authenticated-orcid":false,"given":"Anca-Raluca","family":"Dinu","sequence":"additional","affiliation":[{"name":"Department XVI, Medical Recovery, \u201cVictor Babe\u015f\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Research Center for Assessment of Human Motion and Functionality and Disability, \u201cVictor Babe\u0219s\u201d University of Medicine and Pharmacy, Eftimie Murgu Square, No. 2, 300041 Timisoara, Romania"},{"name":"\u201cPius Brinzeu\u201d Emergency Clinical County Hospital, Bld Liviu Rebreanu, No. 156, 300723 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia Mira","family":"Berceanu-Vaduva","sequence":"additional","affiliation":[{"name":"Discipline of Microbiology, Department XIV Microbiology, University of Medicine and Pharmacy from Timisoara, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Dumitrescu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy from Timisoara, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3034-2365","authenticated-orcid":false,"given":"Tudor-Paul","family":"Tama\u0219","sequence":"additional","affiliation":[{"name":"Discipline of Physiology, Department III\u2014Functional Sciences, University of Medicine and Pharmacy from Timisoara, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0865-0054","authenticated-orcid":false,"given":"Abhinav","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Cardiology\u2014Internal Medicine and Ambulatory Care, Prevention and Cardiovascular Recovery, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela-Diana","family":"Popa","sequence":"additional","affiliation":[{"name":"Discipline of Microbiology, Department XIV Microbiology, University of Medicine and Pharmacy from Timisoara, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.12816\/0003257","article-title":"The history of diabetes mellitus","volume":"13","author":"Lakhtakia","year":"2013","journal-title":"Sultan Qaboos Univ. Med. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"108819","DOI":"10.1016\/j.diabres.2021.108819","article-title":"The history of the Nobel prize for the discovery of insulin","volume":"175","author":"Lindsten","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1023\/B:JOFL.0000039433.01093.e8","article-title":"Progress in glucose sensing","volume":"14","author":"Badugu","year":"2004","journal-title":"J. Fluoresc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1136\/bmj.1.5033.1431","article-title":"Claude Bernard And The Discovery Of Glycogen: A Century Of Retrospect","volume":"1","author":"Young","year":"1957","journal-title":"Br. Med. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1042\/bj0490463","article-title":"The amino-acid sequence in the phenylalanyl chain of insulin. I. The identification of lower peptides from partial hydrolysates","volume":"49","author":"Sanger","year":"1951","journal-title":"Biochem. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1042\/bj0530353","article-title":"The amino-acid sequence in the glycyl chain of insulin. I. The identification of lower peptides from partial hydrolysates","volume":"53","author":"Sanger","year":"1953","journal-title":"Biochem. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1073\/pnas.1120470109","article-title":"Rosalyn Sussman Yalow (1921\u20132011)","volume":"109","author":"Kahn","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"18701","DOI":"10.3402\/jchimp.v2i2.18701","article-title":"History of insulin","volume":"2","author":"Quianzon","year":"2012","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.bi.57.070188.000245","article-title":"Sequences, sequences, and sequences","volume":"57","author":"Sanger","year":"1988","journal-title":"Annu. Rev. Biochem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1042\/bj0590509","article-title":"The amide groups of insulin","volume":"59","author":"Sanger","year":"1955","journal-title":"Biochem. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1126\/science.6337396","article-title":"Human insulin from recombinant DNA technology","volume":"219","author":"Johnson","year":"1983","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"953","DOI":"10.4014\/jmb.1412.12079","article-title":"Production of Biopharmaceuticals in E. coli: Current Scenario and Future Perspectives","volume":"25","author":"Baeshen","year":"2015","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2337\/diacare.5.2.S35","article-title":"Clinical Pharmacology of Human Insulin of Recombinant DNA Origin in Healthy Volunteers","volume":"5","author":"Ebihara","year":"1982","journal-title":"Diabetes Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.16.3.155","article-title":"Immunogenicity and allergenic potential of animal and human insulins","volume":"16","author":"Schernthaner","year":"1993","journal-title":"Diabetes Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1007\/s00125-022-05710-9","article-title":"Insulin allergy: A diagnostic and therapeutic strategy based on a retrospective cohort and a case-control study","volume":"65","author":"Pecquet","year":"2022","journal-title":"Diabetologia"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Chen, S., Chen, H., Jiang, Y., Zheng, X., Zhang, M., Yang, T., and Gu, Y. (2023). Association of subclass distribution of insulin antibody with glucose control in insulin-treated type 2 diabetes mellitus: A retrospective observational study. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1141414"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1205121","DOI":"10.1155\/2018\/1205121","article-title":"Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability","volume":"2018","author":"Gradel","year":"2018","journal-title":"J. Diabetes Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.clnu.2019.04.001","article-title":"Postprandial glucose, insulin and incretin responses differ by test meal macronutrient ingestion sequence (PATTERN study)","volume":"39","author":"Sun","year":"2020","journal-title":"Clin. Nutr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1210\/endrev\/bnaa015","article-title":"The Evolution of Insulin and How it Informs Therapy and Treatment Choices","volume":"41","author":"Hirsch","year":"2020","journal-title":"Endocr. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejps.2014.05.010","article-title":"Insulin aspart pharmacokinetics: An assessment of its variability and underlying mechanisms","volume":"62","author":"Rasmussen","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40262-019-00834-5","article-title":"Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences","volume":"59","author":"Haahr","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2337\/cd20-0119","article-title":"Ultra-Rapid-Acting Insulins: How Fast Is Really Needed?","volume":"39","author":"Wong","year":"2021","journal-title":"Clin. Diabetes"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.diabres.2015.04.002","article-title":"Clinical use of insulin degludec","volume":"109","author":"Vora","year":"2015","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s40262-014-0165-y","article-title":"A review of the pharmacological properties of insulin degludec and their clinical relevance","volume":"53","author":"Haahr","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s11096-022-01410-x","article-title":"Safety, efficacy, and cost-effectiveness of insulin degludec U100 versus insulin glargine U300 in adults with type 1 diabetes: A systematic review and indirect treatment comparison","volume":"44","author":"Martin","year":"2022","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_26","unstructured":"American Society of Health-System Pharmacists (ASHP) (2024, November 01). Drugs.com\u2014Prescription Drug Information. Drug Information for Healthcare Professionals. Available online: https:\/\/www.drugs.com\/professionals.html."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2165\/00003088-200241130-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures","volume":"41","author":"Roach","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.clinthera.2020.07.005","article-title":"Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects","volume":"42","author":"Leohr","year":"2020","journal-title":"Clin. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2337\/diacare.23.5.644","article-title":"Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo","volume":"23","author":"Heinemann","year":"2000","journal-title":"Diabetes Care"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/s41586-024-08042-3","article-title":"Glucose-sensitive insulin with attenuation of hypoglycaemia","volume":"634","author":"Kruse","year":"2024","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2337\/db17-0577","article-title":"Engineering Glucose Responsiveness Into Insulin","volume":"67","author":"Kaarsholm","year":"2017","journal-title":"Diabetes"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2008.08.009","article-title":"Chemically controlled closed-loop insulin delivery","volume":"132","author":"Ravaine","year":"2008","journal-title":"J. Control. Release"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.pep.2004.10.014","article-title":"Expression and purification of exendin-4, a GLP-1 receptor agonist, in Escherichia coli","volume":"41","author":"Yin","year":"2005","journal-title":"Protein Expr. Purif."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.toxicon.2010.12.016","article-title":"The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent","volume":"59","author":"Furman","year":"2012","journal-title":"Toxicon Off. J. Int. Soc. Toxinology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Puddu, A., and Maggi, D. (2024). Special Issue: \u201cAnti-inflammatory Effects of Glucagon-like Peptide-1. \u201d Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25041997"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"eadg3456","DOI":"10.1126\/scitranslmed.adg3456","article-title":"Harmine and exendin-4 combination therapy safely expands human \u03b2 cell mass in vivo in a mouse xenograft system","volume":"16","author":"Rosselot","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., and Zhang, X.-F. (2023). GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1085799"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMc2302677","article-title":"Semaglutide in Early Type 1 Diabetes","volume":"389","author":"Dandona","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2337\/diabetes.47.4.640","article-title":"Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans","volume":"47","author":"Kahn","year":"1998","journal-title":"Diabetes"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"105965","DOI":"10.1016\/j.appet.2022.105965","article-title":"Creating the amylin story","volume":"172","author":"Lutz","year":"2022","journal-title":"Appetite"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1124\/jpet.123.001679","article-title":"Pramlintide an Adjunct to Insulin Therapy: Challenges and Recent Progress in Delivery","volume":"388","author":"Kommera","year":"2024","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2337\/db09-1655","article-title":"Physiologic and pharmacologic modulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta-cells by peroxisome proliferator-activated receptor (PPAR)-gamma signaling: Possible mechanism for the GIP resistance in type 2 diabetes","volume":"59","author":"Gupta","year":"2010","journal-title":"Diabetes"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Shekhawat, V.S., Bhansali, S., Dutta, P., Mukherjee, K.K., Vaiphei, K., Kochhar, R., Sinha, S.K., Sachdeva, N., Kurpad, A.V., and Bhat, K. (2019). Glucose-dependent Insulinotropic Polypeptide (GIP) Resistance and \u03b2-cell Dysfunction Contribute to Hyperglycaemia in Acromegaly. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-41887-7"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How May GIP Enhance the Therapeutic Efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3945\/ajcn.2008.26720","article-title":"Prolonged saturated fat\u2013induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: Dysregulated enteroadipocyte axis as a novel feature of fatty liver2","volume":"89","author":"Musso","year":"2009","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Davies","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e2710","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomized Clinical Trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12933-024-02319-7","article-title":"Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: Evidence for the role of tirzepatide","volume":"23","author":"Taktaz","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s11154-023-09825-1","article-title":"Beyond glycemia: Comparing tirzepatide to GLP-1 analogues","volume":"24","author":"Andraos","year":"2023","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"106874","DOI":"10.1016\/j.domaniend.2024.106874","article-title":"The glucagon-receptor antagonist MK-3577 reduces glucagon-stimulated plasma glucose and insulin concentrations in metabolically healthy overweight cats","volume":"89","author":"Mott","year":"2024","journal-title":"Domest. Anim. Endocrinol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrendo.2010.187","article-title":"The metabolic actions of glucagon revisited","volume":"6","author":"Habegger","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"(2023). Erica Chow; Stephen Clement; Rajesh Garg Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. BMJ Open Diabetes Res. Care, 11, e003666.","DOI":"10.1136\/bmjdrc-2023-003666"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Boeder, S.C., Thomas, R.L., Le Roux, M.J., Giovannetti, E.R., Gregory, J.M., and Pettus, J.H. (2024). Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial. Diabetes Care, dc240212.","DOI":"10.2337\/dc24-0212"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/bph.16336","article-title":"Characterisation of cotadutide\u2019s dual GLP-1\/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model","volume":"181","author":"Bosch","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1111\/dom.15693","article-title":"Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity","volume":"26","author":"Winther","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"333-OR","DOI":"10.2337\/db22-333-OR","article-title":"333-OR: Oxyntomodulin Analog LY3305677 (LY) Improves Glycemic Control and Weight Loss in Healthy Volunteers and Subjects with Type 2 Diabetes (T2D)","volume":"71","author":"Benson","year":"2022","journal-title":"Diabetes"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"170955","DOI":"10.1016\/j.peptides.2023.170955","article-title":"Emerging roles of oxyntomodulin-based glucagon-like peptide-1\/glucagon co-agonist analogs in diabetes and obesity","volume":"162","author":"Yao","year":"2023","journal-title":"Peptides"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013Hormone-Receptor Agonist Retatrutide for Obesity\u2014A Phase 2 Trial","volume":"389","author":"Wu","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Chen, J., Huang, Y., Liu, C., Chi, J., Wang, Y., and Xu, L. (2023). The role of C-peptide in diabetes and its complications: An updated review. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1256093"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.7150\/thno.81714","article-title":"Therapeutic effect of ultra-long-lasting human C-peptide delivery against hyperglycemia-induced neovascularization in diabetic retinopathy","volume":"13","author":"Moon","year":"2023","journal-title":"Theranostics"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2337\/dbi23-0012","article-title":"Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes","volume":"73","author":"Latres","year":"2024","journal-title":"Diabetes"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"174039","DOI":"10.1016\/j.ejphar.2021.174039","article-title":"A ghrelin receptor antagonist reduces the ability of ghrelin, alcohol or amphetamine to induce a dopamine release in the ventral tegmental area and in nucleus accumbens shell in rats","volume":"899","author":"Edvardsson","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Lu, X., Huang, L., Huang, Z., Feng, D., Clark, R.J., and Chen, C. (2021). LEAP-2: An Emerging Endogenous Ghrelin Receptor Antagonist in the Pathophysiology of Obesity. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.717544"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Merritt, C.R., Garcia, E.J., Brehm, V.D., Fox, R.G., Moeller, F.G., Anastasio, N.C., and Cunningham, K.A. (2023). Ghrelin receptor antagonist JMV2959 blunts cocaine and oxycodone drug-seeking, but not self-administration, in male rats. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1268366"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40842-024-00181-w","article-title":"Teplizumab\u2019s immunomodulatory effects on pancreatic \u03b2-cell function in type 1 diabetes mellitus","volume":"10","author":"Aderinto","year":"2024","journal-title":"Clin. Diabetes Endocrinol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.2337\/dc23-0675","article-title":"Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves \u03b2-Cell Function","volume":"46","author":"Herold","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Rimon, M.T.I., Hasan, M.W., Hassan, M.F., and Cesmeci, S. (2024). Advancements in Insulin Pumps: A Comprehensive Exploration of Insulin Pump Systems, Technologies, and Future Directions. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16070944"},{"key":"ref_71","first-page":"125","article-title":"Insulin pump therapy: Acceptable alternative to injection therapy","volume":"99","author":"Marcus","year":"1996","journal-title":"Postgrad. Med."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2002). Standards of Medical Care for Patients with Diabetes Mellitus. Diabetes Care, 25, s33\u2013s49.","DOI":"10.2337\/diacare.25.2007.S33"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1089\/dia.2008.0134","article-title":"The integrated MiniMed Paradigm REAL-Time insulin pump and glucose monitoring system: Implications for improved patient outcomes","volume":"11","author":"Mastrototaro","year":"2009","journal-title":"Diabetes Technol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"612","DOI":"10.4158\/EP15984.RA","article-title":"The Role of Glucagon in the Pathophysiology and Management of Diabetes","volume":"22","author":"Kulina","year":"2016","journal-title":"Endocr. Pract."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dc18-0228","article-title":"Randomized Outpatient Trial of Single- and Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors","volume":"41","author":"Castle","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_76","first-page":"178","article-title":"Long-term sensor-augmented pump therapy for neonatal diabetes mellitus: A case series","volume":"31","author":"Fukuda","year":"2022","journal-title":"Clin. Pediatr. Endocrinol. Case Rep. Clin. Investig. Off. J. Jpn. Soc. Pediatr. Endocrinol."},{"key":"ref_77","first-page":"100306","article-title":"Long-term efficacy of sensor-augmented pump therapy (Minimed 640G system) combined with a telemedicine follow-up in patients with type 1 diabetes: A real life study","volume":"30","author":"Notemi","year":"2022","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2337\/cd20-0042","article-title":"Time in Range: How to Measure It, How to Report It, and Its Practical Application in Clinical Decision-Making","volume":"38","author":"Wright","year":"2020","journal-title":"Clin. Diabetes"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1177\/19322968231156601","article-title":"Use of Continuous Glucose Monitoring in Pump Therapy Sensor Augmented Pump or Automated Insulin Delivery in Different Age Groups (0.5 to <26 Years) with Type 1 Diabetes From 2018 to 2021: Analysis of the German\/Austrian\/Swiss\/Luxemburg Diabetes Prospective Follow-up Database Registry","volume":"18","author":"Auzanneau","year":"2024","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00125-024-06155-y","article-title":"Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: A multicentre randomised controlled trial","volume":"67","author":"Kim","year":"2024","journal-title":"Diabetologia"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa061267","article-title":"International Trial of the Edmonton Protocol for Islet Transplantation","volume":"355","author":"Shapiro","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMc1613959","article-title":"Bioengineering of an Intraabdominal Endocrine Pancreas","volume":"376","author":"Baidal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s42255-020-0269-7","article-title":"Islet transplantation in the subcutaneous space achieves long-term euglycaemia in preclinical models of type 1 diabetes","volume":"2","author":"Yu","year":"2020","journal-title":"Nat. Metab."},{"key":"ref_84","first-page":"2816","article-title":"Autologous regulatory T cells in clinical intraportal allogenic pancreatic islet transplantation","volume":"34","author":"Yao","year":"2021","journal-title":"Transpl. Int. Off. J. Eur. Soc. Organ Transplant."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Wang, Q., Huang, Y.-X., Liu, L., Zhao, X.-H., Sun, Y., Mao, X., and Li, S.-W. (2024). Pancreatic islet transplantation: Current advances and challenges. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1391504"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00018-022-04369-0","article-title":"Microencapsulation-based cell therapies","volume":"79","author":"Marikar","year":"2022","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1186\/s12967-024-05226-3","article-title":"Advances and challenges of the cell-based therapies among diabetic patients","volume":"22","author":"Raoufinia","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"eadf6376","DOI":"10.1126\/scitranslmed.adf6376","article-title":"The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates","volume":"15","author":"Anwar","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/01.tp.0000994460.57811.03","article-title":"318.5: Emerging Data from a Study of Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients: Implications for a Similar Study in Islet Cell Transplantation","volume":"107","author":"Gill","year":"2023","journal-title":"Transplantation"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S2213-8587(23)00082-7","article-title":"Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: A retrospective, multicentre, observational cohort study in 1210 patients from the Collaborative Islet Transplant Registry","volume":"11","author":"Chetboun","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_91","first-page":"10335","article-title":"Estimation of Early Graft Function Using the BETA-2 Score Following Clinical Islet Transplantation","volume":"35","author":"Lam","year":"2022","journal-title":"Transpl. Int. Off. J. Eur. Soc. Organ Transplant."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S2213-8587(22)00114-0","article-title":"Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada","volume":"10","author":"Imes","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1111\/ajt.16637","article-title":"Ten-year outcomes of islet transplantation in patients with type 1 diabetes: Data from the Swiss-French GRAGIL network","volume":"21","author":"Lablanche","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/19382014.2021.1941555","article-title":"The Potential of Pancreatic Organoids for Diabetes Research and Therapy","volume":"13","author":"Bittenglova","year":"2021","journal-title":"Islets"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Casamitjana, J., Espinet, E., and Rovira, M. (2022). Pancreatic Organoids for Regenerative Medicine and Cancer Research. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.886153"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Nath, S.C., Menendez, L., and Friedrich Ben-Nun, I. (2023). Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242316929"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13046-020-01584-0","article-title":"Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells","volume":"39","author":"Wuputra","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1517\/13543784.6.8.1041","article-title":"New non-sulfonylurea insulin secretagogues","volume":"6","author":"Dunning","year":"1997","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Pinho, A.V., Bensellam, M., Wauters, E., Rees, M., Giry-Laterriere, M., Mawson, A., Ly, L.Q., Biankin, A.V., Wu, J., and Laybutt, D.R. (2015). Pancreas-Specific Sirt1-Deficiency in Mice Compromises Beta-Cell Function without Development of Hyperglycemia. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128012"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Cudini, A., and Fierabracci, A. (2023). Advances in Immunotherapeutic Approaches to Type 1 Diabetes. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119220"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Su, J., Xu, J., Hu, S., Ye, H., Xie, L., and Ouyang, S. (2024). Advances in small-molecule insulin secretagogues for diabetes treatment. Biomed. Pharmacother., 178.","DOI":"10.1016\/j.biopha.2024.117179"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"122565","DOI":"10.1016\/j.ijpharm.2022.122565","article-title":"Efficient delivery of VEGF-A mRNA for promoting diabetic wound healing via ionizable lipid nanoparticles","volume":"632","author":"Zha","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.stem.2017.11.020","article-title":"Endogenous Reprogramming of Alpha Cells into Beta Cells, Induced by Viral Gene Therapy, Reverses Autoimmune Diabetes","volume":"22","author":"Xiao","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41421-024-00662-3","article-title":"Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue","volume":"10","author":"Wu","year":"2024","journal-title":"Cell Discov."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/j.celrep.2018.02.006","article-title":"P2RY1\/ALK3-Expressing Cells within the Adult Human Exocrine Pancreas Are BMP-7 Expandable and Exhibit Progenitor-like Characteristics","volume":"22","author":"Qadir","year":"2018","journal-title":"Cell Rep."},{"key":"ref_106","first-page":"e941918","article-title":"Editorial: First Regulatory Approval for Allogeneic Pancreatic Islet Beta Cell Infusion for Adult Patients with Type 1 Diabetes Mellitus","volume":"29","author":"Parums","year":"2023","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/12\/1563\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:49:35Z","timestamp":1760114975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/12\/1563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,7]]},"references-count":106,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["biom14121563"],"URL":"https:\/\/doi.org\/10.3390\/biom14121563","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,7]]}}}